The Seraph 100® Microbind Affinity Blood Filter Does Not Alter Levels of Circulating or Mucosal Antibodies in Critical COVID-19 Patients [0.03%]
塞拉非100微结合亲和力血液滤过器不会改变重度COVID-19患者循环或粘膜抗体水平
Tonia L Conner,Pooja Vir,Eric D Laing et al.
Tonia L Conner et al.
PURIFY-OBS-1 is an observational study evaluating the safety and efficacy of Seraph 100® Microbind Affinity Blood Filter (Seraph 100) use for COVID-19 patients with respiratory failure admitted to the intensive care unit (ICU). The Seraph ...
Prevention of Blood Incompatibility Related Hemagglutination: Blocking of Antigen A on Red Blood Cells Using In Silico Designed Recombinant Anti-A scFv [0.03%]
利用计算机设计重组Anti-A单链抗体阻断红细胞A抗原预防血型不合相关溶血
Saleha Hafeez,Najam Us Sahar Sadaf Zaidi
Saleha Hafeez
Critical blood shortages plague healthcare systems, particularly in lower-income and middle-income countries. This affects patients requiring regular transfusions and creates challenges during emergencies where universal blood is vital. To ...
Knowledge of the Serological Response to the Third BNT162b2 Vaccination May Influence Compliance of Healthcare Workers to Booster Dose [0.03%]
第三剂BNT162b2疫苗血清学反应的知识可能会影响医护人员接种加强针的依从性
Avi Magid,Khetam Hussein,Halima Dabaja-Younis et al.
Avi Magid et al.
Background: Previous studies showed that the fourth SARS-CoV-2 vaccine dose has a protective effect against infection, as well as against severe disease and death. This study aimed to examine whether knowledge of a high-l...
Novel Flow Cytometry Method Detecting Complement C1q Bound to Blood Type A/B IgG Antibody for Preventing Severe Antibody-Mediated Rejection in ABO-Incompatible Kidney Transplantation [0.03%]
一种新型流式细胞仪检测技术可检测血型A或Bigg抗体结合补体C1q以预防ABO不匹配肾移植后的严重移植物排斥反应
Tsutomu Ishizuka,Kazuhiro Iwadoh,Hiroshi Kataoka et al.
Tsutomu Ishizuka et al.
We aimed to develop a novel method for measuring the complement-binding ability of anti-blood type antibodies (ab-Abs), the flow cytometry method for the complement C1q test (FCM-C1q) for detecting antibody-mediated rejection (AMR) caused b...
Allogeneic HLA Humoral Immunogenicity and the Prediction of Donor-Specific HLA Antibody Development [0.03%]
同种异体HLA抗体免疫原性和供者特异性HLA抗体产生的预测
Vadim Jucaud
Vadim Jucaud
The development of de novo donor-specific HLA antibodies (dnDSAs) following solid organ transplantation is considered a major risk factor for poor long-term allograft outcomes. The prediction of dnDSA development is a boon to transplant rec...
Application of Monoclonal Antibodies against Naturally Occurring Bioactive Ingredients [0.03%]
单克隆抗体在识别天然活性物质方面的应用
Shunsuke Fujii,Takuhiro Uto,Hiroaki Hayashi et al.
Shunsuke Fujii et al.
Monoclonal antibodies (Mabs) are widely used in a variety of fields, including protein identification, life sciences, medicine, and natural product chemistry. This review focuses on Mabs against naturally occurring active compounds. The pre...
Adverse Events of PD-1, PD-L1, CTLA-4, and LAG-3 Immune Checkpoint Inhibitors: An Analysis of the FDA Adverse Events Database [0.03%]
PD-1、PD-L1、CTLA-4和LAG-3免疫检查点抑制剂的不良事件：美国FDA不良事件数据库分析
Connor Frey,Mahyar Etminan
Connor Frey
This study aimed to identify the 25 most prevalent adverse events (AEs) associated with FDA-approved immune checkpoint inhibitors (ICIs)-specifically, PD-1, PD-L1, CTLA-4, and LAG-3 inhibitors-using data from the FDA Adverse Events Reportin...
Monique Vogel,Paul Engeroff
Monique Vogel
Immunoglobulin E (IgE) plays a critical role for the immune system, fighting against parasites, toxins, and cancer. However, when it reacts to allergens without proper regulation, it can cause allergic reactions, including anaphylaxis, thro...
Humanization of Pan-HLA-DR mAb 44H10 Hinges on Critical Residues in the Antibody Framework [0.03%]
全HLA-DR抗体44H10的人源化依赖于抗体骨架上的关键残基
Audrey Kassardjian,Danton Ivanochko,Brian Barber et al.
Audrey Kassardjian et al.
Reducing the immunogenicity of animal-derived monoclonal antibodies (mAbs) for use in humans is critical to maximize therapeutic effectiveness and preclude potential adverse events. While traditional humanization methods have primarily focu...
Immune-Related Adverse Events Associated with Atezolizumab: Insights from Real-World Pharmacovigilance Data [0.03%]
阿特朱单抗相关免疫不良事件：来自真实世界药物警戒数据的见解
Connor Frey,Mahyar Etminan
Connor Frey
The advancement of immuno-oncology has brought about a significant shift in cancer treatment methods, with antibody-based immune checkpoint inhibitors like atezolizumab leading the way in this regard. However, the use of this checkpoint blo...